Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03987204 · ClinicalTrials.gov registry record · Phase 1
Ivabradine for Rate Control in Permanent Atrial Fibrillation
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03987204 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 4 participants.
The verdict
NCT03987204, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Ivabradine may be useful as a rate controlling agent in atrial fibrillation without negative effects on hemodynamics and inotropy. The objective in this proof of concept study is to investigate the hypothesis that ivabradine will slow the ventricular response in patients with permanent atrial fibrillation and previously-implanted pacemakers.
Interventions
- DRUG Ivabradine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-06-15 |
| Est. Completion | 2019-09-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03987204
The ClinicalTrials.gov registry entry for NCT03987204 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ivabradine is the first listed.
NCT03987204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03987204 about?
NCT03987204 is a clinical study titled "Ivabradine for Rate Control in Permanent Atrial Fibrillation". Ivabradine may be useful as a rate controlling agent in atrial fibrillation without negative effects on hemodynamics and inotropy. The objective in this proof of concept study is to investigate the hypothesis that ivabradine will slow the ventricular response in patients with permanent atrial fibril...
What is the current status of trial NCT03987204?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2019-06-15. Estimated completion is 2019-09-17.
What interventions are being tested in trial NCT03987204?
The interventions under investigation include: Ivabradine (DRUG).
Who is sponsoring clinical trial NCT03987204?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.